Lilly Reconfirms Its Financial Guidance
INDIANAPOLIS, Ind., Jan 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Concurrent with today's announcement entitled "Lilly and Boehringer Ingelheim Jointly Announce the Recision of U.S. FDA Application for Duloxetine for Treatment of Stress Urinary Incontinence," Eli Lilly and Company (NYSE: LLY) is reconfirming its financial guidance for the first quarter and full year of 2005. This financial guidance is detailed in the company's financial results press release and related Form 8-K dated January 26, 2005.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY
This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as competitive developments affecting current growth products; rate of sales growth of recently launched products; the timing of anticipated regulatory approvals and launches of new products; other regulatory developments and government investigations; patent disputes and other litigation involving current and future products (including the outcome of the Zyprexa(R) patent litigation that was tried in front of the federal district court in Indianapolis in January and February 2004); the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; changes in tax law; and the impact of exchange rates. For additional information about the factors that affect the company's business, please see Exhibit 99 to the company's latest Form 10-Q filed November 2004. The company undertakes no duty to update forward-looking statements.
Zyprexa(R) (olanzapine, Lilly)
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
Terra Fox of Eli Lilly and Company, +1-317-276-5795
http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX